Italy's DiaSorin ex-Covid revenue in line with guidance

DiaSorin SpA

14/03/2025 16:25

March 14 (Reuters) - Italian medical diagnostics group DiaSorin DIAS.MI on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.

The group's 2024 revenue increased 3% year-on-year at constant exchange rates to 1.18 billion euros ($1.28 billion), while revenue was up 7% when excluding its COVID-related business, in line with guidance.

The group proposed a dividend of 1.20 euro per share.

Shares were 2.6% lower after the results.

 (Reporting by Michela Stasio; Editing by Kirsten Donovan)

 ((Michela.Stasio@thomsonreuters.com;))